As Phillips 66 Partners LP (PSXP) Stock Price Rose, Shareholder Energy Income Partners Boosted Its Holding; Dupont Capital Management Has Decreased Eagle Pharmaceuticals (EGRX) Stake by $504,348; Stock Price Rose

June 2, 2018 - By Dolores Ford

Dupont Capital Management Corp decreased its stake in Eagle Pharmaceuticals Inc (EGRX) by 64.08% based on its latest 2018Q1 regulatory filing with the SEC. Dupont Capital Management Corp sold 9,699 shares as the company’s stock rose 9.55% while stock markets declined. The institutional investor held 5,436 shares of the health care company at the end of 2018Q1, valued at $286,000, down from 15,135 at the end of the previous reported quarter. Dupont Capital Management Corp who had been investing in Eagle Pharmaceuticals Inc for a number of months, seems to be less bullish one the $996.35 million market cap company. The stock decreased 0.37% or $0.25 during the last trading session, reaching $67.16. About 220,063 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 9.68% since June 2, 2017 and is downtrending. It has underperformed by 22.25% the S&P500.

Energy Income Partners Llc increased its stake in Phillips 66 Partners Lp (PSXP) by 0.43% based on its latest 2018Q1 regulatory filing with the SEC. Energy Income Partners Llc bought 10,970 shares as the company’s stock rose 1.02% while stock markets declined. The hedge fund held 2.58 million shares of the natural gas distribution company at the end of 2018Q1, valued at $123.46 million, up from 2.57M at the end of the previous reported quarter. Energy Income Partners Llc who had been investing in Phillips 66 Partners Lp for a number of months, seems to be bullish on the $6.48B market cap company. The stock increased 1.68% or $0.88 during the last trading session, reaching $53.18. About 210,869 shares traded. Phillips 66 Partners LP (NYSE:PSXP) has declined 1.78% since June 2, 2017 and is downtrending. It has underperformed by 14.35% the S&P500.

Energy Income Partners Llc, which manages about $4.12B and $5.13B US Long portfolio, decreased its stake in Eversource Energy by 913,127 shares to 280,423 shares, valued at $16.52M in 2018Q1, according to the filing. It also reduced its holding in Enbridge Inc (NYSE:ENB) by 762,150 shares in the quarter, leaving it with 2.17 million shares, and cut its stake in Alliance Res Partner LP (NASDAQ:ARLP).

Among 16 analysts covering Phillips 66 Partners (NYSE:PSXP), 10 have Buy rating, 0 Sell and 6 Hold. Therefore 63% are positive. Phillips 66 Partners had 55 analyst reports since August 4, 2015 according to SRatingsIntel. Morgan Stanley maintained the stock with “Overweight” rating in Friday, November 17 report. Stifel Nicolaus maintained it with “Buy” rating and $60 target in Monday, September 25 report. Goldman Sachs initiated Phillips 66 Partners LP (NYSE:PSXP) on Thursday, August 25 with “Neutral” rating. The firm has “Overweight” rating given on Tuesday, March 13 by JP Morgan. The rating was upgraded by Credit Suisse to “Outperform” on Monday, October 26. Stifel Nicolaus maintained the shares of PSXP in report on Thursday, July 27 with “Buy” rating. The stock has “Buy” rating by Evercore on Thursday, September 3. Citigroup upgraded Phillips 66 Partners LP (NYSE:PSXP) on Wednesday, January 25 to “Buy” rating. The rating was maintained by Jefferies with “Hold” on Thursday, June 1. Stifel Nicolaus maintained Phillips 66 Partners LP (NYSE:PSXP) on Thursday, October 26 with “Buy” rating.

Investors sentiment increased to 1.43 in Q1 2018. Its up 0.46, from 0.97 in 2017Q4. It is positive, as 13 investors sold PSXP shares while 31 reduced holdings. 19 funds opened positions while 44 raised stakes. 45.71 million shares or 0.36% more from 45.55 million shares in 2017Q4 were reported. 10,653 are owned by Stifel Fincl. Nelson Van Denburg Campbell Wealth Management Grp Llc has 4,770 shares for 0.05% of their portfolio. Goodwin Daniel L has invested 0.21% in Phillips 66 Partners LP (NYSE:PSXP). Atlantic Trust Group Lc invested in 0.02% or 77,296 shares. Glenmede Communications Na reported 54,686 shares. Morgan Stanley reported 679,681 shares. Monetary Gp has 0.04% invested in Phillips 66 Partners LP (NYSE:PSXP). Westwood Grp holds 0.44% or 1.15 million shares in its portfolio. Benjamin F Edwards & Communications has invested 0% in Phillips 66 Partners LP (NYSE:PSXP). Freestone Cap Lc reported 92,915 shares. Bank & Trust Of America De accumulated 237,954 shares. Deutsche National Bank Ag owns 0% invested in Phillips 66 Partners LP (NYSE:PSXP) for 132,807 shares. Country Club Company Na reported 6,273 shares. Parkside Fincl Fincl Bank reported 26,885 shares. Engy Income Partners Ltd Limited Liability Company owns 2.58 million shares.

More notable recent Phillips 66 Partners LP (NYSE:PSXP) news were published by: Bizjournals.com which released: “Houston midstream co. cancels pipeline open season” on May 08, 2018, also Investorplace.com with their article: “5 MLPs That Should Crush the Market in 2018” published on May 17, 2018, Seekingalpha.com published: “Will Phillips 66 Roll-Up Its MLP?” on May 20, 2018. More interesting news about Phillips 66 Partners LP (NYSE:PSXP) were released by: Seekingalpha.com and their article: “Q1’18 MLP Distribution Recap: Several Growers Overshadowed By 2 Cuts” published on May 23, 2018 as well as Seekingalpha.com‘s news article titled: “Phillips 66 Is Cashing In On The Oil Spread” with publication date: May 21, 2018.

More notable recent Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) news were published by: Businesswire.com which released: “Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June” on May 29, 2018, also Nasdaq.com with their article: “Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial …” published on May 17, 2018, Streetinsider.com published: “Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 16c, Miss on Revenues” on May 10, 2018. More interesting news about Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were released by: Streetinsider.com and their article: “Eagle Pharmaceuticals (EGRX) Says it was Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to …” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Eagle Pharmaceuticals’ (EGRX) CEO Scott Tarriff on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Dupont Capital Management Corp, which manages about $36.48 billion and $4.14B US Long portfolio, upped its stake in Synnex Corp (NYSE:SNX) by 2,738 shares to 32,438 shares, valued at $3.84 million in 2018Q1, according to the filing. It also increased its holding in Allegion Plc (NYSE:ALLE) by 7,644 shares in the quarter, for a total of 179,268 shares, and has risen its stake in General Cable Corp (NYSE:BGC).

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 26 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained it with “Buy” rating and $79.0 target in Tuesday, January 30 report. The firm has “Buy” rating by RBC Capital Markets given on Friday, September 1. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Monday, May 7 with “Sell” rating. As per Thursday, May 17, the company rating was maintained by Mizuho. On Monday, February 26 the stock rating was maintained by RBC Capital Markets with “Buy”. Mizuho maintained the shares of EGRX in report on Wednesday, October 26 with “Buy” rating. Piper Jaffray maintained the shares of EGRX in report on Tuesday, July 25 with “Buy” rating. As per Thursday, November 3, the company rating was upgraded by Mizuho. The rating was maintained by Piper Jaffray with “Overweight” on Wednesday, July 29. On Monday, January 9 the stock rating was downgraded by Mizuho to “Underperform”.

Phillips 66 Partners LP (NYSE:PSXP) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>